A recently published paper called ‘Biallelic loss of human CTNNA2, encoding αN-catenin, leads to ARP2/3 complex overactivity and disordered cortical neuronal migration’ outlines new research into the genetic basis of…
According to a story from Gloucestershire Live, Emma Robinson, who is only 46 years old, was just told by her doctors that she has terminal cancer. She had vulvar cancer,…
According to 9News, Harry Campbell was born very premature at 27 weeks. Not only this, but his dimensions were almost unfathomable. Harry was able to fit into the palm of…
Gemphire Therapeutics Inc. has been recommended to stop a clinical trial by the Data and Safety Monitoring Board at Emory University School of Medicine. The clinical trial, which ran into…
Let's take a moment during these dog days of summer to recognize the SMA community during SMA awareness month! Spinal muscular atrophy (SMA) is a rare genetic disorder that causes…
The company Epizyme has announced the results of a Phase 2 clinical study of its lead candidate drug, tazemetostat, in the treatment of relapsed or refractory malignant mesothelioma with loss…
A motor neurone disease clinical drug trial will take place in Scotland for the first time in more than twenty years. This study is the first step in a broader…
The top-line results of a pivotal Phase 3 study investigating the drug recorlevTM (levoketoconazole) in patients with endogenous Cushing’s syndrome have been released. The source article, which contains more detailed information,…
An investigational drug called ALT-P7 is being developed as a potential medicine for certain forms of cancer. The drug has received Orphan Drug Designation for the treatment of gastric cancer…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
